185 related articles for article (PubMed ID: 31135582)
1. Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
Crane HM; Nance RM; Heckbert SR; Ritchings C; Rosenblatt L; Budoff M; Wood BR; Tirschwell DL; Kim HN; Mathews WC; Geng E; Moore RD; Hunt PW; Eron JJ; Burkholder GA; Drozd DR; Chow FC; Becker KJ; Zunt JR; Ho EL; Kalani R; Huffer A; Whitney BM; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):e141-e147. PubMed ID: 31135582
[TBL] [Abstract][Full Text] [Related]
2. Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS).
Feinstein MJ; Nance RM; Delaney JAC; Heckbert SR; Budoff MJ; Drozd DR; Burkholder GA; Willig JH; Mugavero MJ; Mathews WC; Moore RD; Eron JJ; Napravnik S; Hunt PW; Geng E; Hsue P; Peter I; Lober WB; Crothers K; Grunfeld C; Saag MS; Kitahata MM; Lloyd-Jones DM; Crane HM
BMC Med; 2019 Jul; 17(1):149. PubMed ID: 31362721
[TBL] [Abstract][Full Text] [Related]
3. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Li M; Chan WW; Zucker SD
J Am Heart Assoc; 2020 Oct; 9(19):e016310. PubMed ID: 32930032
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Differences in Types of Myocardial Infarctions Among People Aging With HIV.
Crane HM; Nance RM; Whitney BM; Heckbert SR; Budoff M; High K; Landay A; Feinstein M; Moore RD; Mathews WC; Christopoulos K; Saag MS; Willig A; Eron JJ; Kitahata MM; Delaney JAC;
J Acquir Immune Defic Syndr; 2021 Feb; 86(2):208-212. PubMed ID: 33433123
[TBL] [Abstract][Full Text] [Related]
5. Associations between alcohol and cigarette use and type 1 and 2 myocardial infarction among people with HIV.
Drumright LN; Nance RM; Ruderman SA; Ma J; Whitney BM; Hahn A; Fredericksen RJ; Luu B; Lober WB; Moore RD; Budoff MJ; Keruly JC; Christopoulos K; Puryear S; Willig A; Cropsey K; Mathews WC; Cachay E; Bamford L; Eron JJ; Napravnik S; Mayer KH; O'Cleirigh C; Mccaul ME; Chander G; Feinstein MJ; Saag MS; Kitahata MM; Heckbert SR; Crane HM; Delaney JAC
HIV Med; 2023 Jun; 24(6):703-715. PubMed ID: 36855253
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.
Nance RM; Crane HM; Ritchings C; Rosenblatt L; Budoff M; Heckbert SR; Drozd DR; Mathews WC; Geng E; Hunt PW; Feinstein MJ; Moore RD; Hsue P; Eron JJ; Burkholder GA; Rodriguez B; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):916-921. PubMed ID: 29984593
[TBL] [Abstract][Full Text] [Related]
7. Association Between Chronic Hepatitis C Virus Infection and Myocardial Infarction Among People Living With HIV in the United States.
Williams-Nguyen J; Hawes SE; Nance RM; Lindström S; Heckbert SR; Kim HN; Mathews WC; Cachay ER; Budoff M; Hurt CB; Hunt PW; Geng E; Moore RD; Mugavero MJ; Peter I; Kitahata MM; Saag MS; Crane HM; Delaney JA
Am J Epidemiol; 2020 Jun; 189(6):554-563. PubMed ID: 31712804
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
[TBL] [Abstract][Full Text] [Related]
9. Chronic obstructive pulmonary disease and the risk for myocardial infarction by type in people with HIV.
Crothers K; Nance RM; Whitney BM; Harding BN; Heckbert SR; Budoff MJ; Mathews WC; Bamford L; Cachay ER; Eron JJ; Napravnik S; Moore RD; Keruly JC; Willig A; Burkholder G; Feinstein MJ; Saag MS; Kitahata MM; Crane HM; Delaney JAC;
AIDS; 2023 Apr; 37(5):745-752. PubMed ID: 36728918
[TBL] [Abstract][Full Text] [Related]
10. Polygenic risk scores point toward potential genetic mechanisms of type 2 myocardial infarction in people with HIV.
Lee WJ; Cheng H; Whitney BM; Nance RM; Britton SR; Jordahl K; Lindstrom S; Ruderman SA; Kitahata MM; Saag MS; Willig AL; Burkholder G; Eron JJ; Kovacic JC; Björkegren JLM; Mathews WC; Cachay E; Feinstein MJ; Budoff M; Hunt PW; Moore RD; Keruly J; McCaul ME; Chander G; Webel A; Mayer KH; Delaney JA; Crane PK; Martinez C; Crane HM; Hao K; Peter I
Int J Cardiol; 2023 Jul; 383():15-23. PubMed ID: 37149004
[TBL] [Abstract][Full Text] [Related]
11. Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Costagliola D; Potard V; Lang S; de Castro N; Cotte L; Duval X; Duvivier C; Grabar S; Mary-Krause M; Partisani M; Ronot-Bregigeon S; Simon A; Tattevin P; Weiss L; Zucman D; Katlama C; Raffi F; Boccara F
J Infect Dis; 2020 Feb; 221(4):516-522. PubMed ID: 31828320
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.
LaFleur J; Bress AP; Rosenblatt L; Crook J; Sax PE; Myers J; Ritchings C
AIDS; 2017 Sep; 31(15):2095-2106. PubMed ID: 28692532
[TBL] [Abstract][Full Text] [Related]
13. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV.
Elion RA; Althoff KN; Zhang J; Moore RD; Gange SJ; Kitahata MM; Crane HM; Drozd DR; Stein JH; Klein MB; Eron JJ; Silverberg MJ; Mathews WC; Justice AC; Sterling TR; Rabkin CS; Mayor AM; Klein DB; Horberg MA; Bosch RJ; Eyawo O; Palella FJ;
J Acquir Immune Defic Syndr; 2018 May; 78(1):62-72. PubMed ID: 29419568
[TBL] [Abstract][Full Text] [Related]
14. Type 2 myocardial infarction: A descriptive analysis and comparison with type 1 myocardial infarction.
Landes U; Bental T; Orvin K; Vaknin-Assa H; Rechavia E; Iakobishvili Z; Lev E; Assali A; Kornowski R
J Cardiol; 2016 Jan; 67(1):51-6. PubMed ID: 25956551
[TBL] [Abstract][Full Text] [Related]
15. Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort.
Raphael CE; Roger VL; Sandoval Y; Singh M; Bell M; Lerman A; Rihal CS; Gersh BJ; Lewis B; Lennon RJ; Jaffe AS; Gulati R
Circulation; 2020 Feb; 141(6):454-463. PubMed ID: 31902228
[TBL] [Abstract][Full Text] [Related]
16. Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography.
Gaggin HK; Liu Y; Lyass A; van Kimmenade RR; Motiwala SR; Kelly NP; Mallick A; Gandhi PU; Ibrahim NE; Simon ML; Bhardwaj A; Belcher AM; Harisiades JE; Massaro JM; D'Agostino RB; Januzzi JL
Circulation; 2017 Jan; 135(2):116-127. PubMed ID: 27881568
[TBL] [Abstract][Full Text] [Related]
17. Six-month cardiovascular prognostic impact of type 1 And type 2 myocardial infarction in patients hospitalized for gastrointestinal bleeding.
Pemmasani G; Ashwath A; Aronow WS; Yandrapalli S; Leighton J; John S
Eur J Intern Med; 2023 Oct; 116():51-57. PubMed ID: 37500309
[TBL] [Abstract][Full Text] [Related]
18. Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.
Leger P; Chirwa S; Nwogu JN; Turner M; Richardson DM; Baker P; Leonard M; Erdem H; Olson L; Haas DW
Pharmacogenet Genomics; 2018 Jan; 28(1):1-6. PubMed ID: 29117017
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Insomnia and Risk of Myocardial Infarction Among People With HIV.
Luu BR; Nance RM; Delaney JAC; Ruderman SA; Heckbert SR; Budoff MJ; Mathews WC; Moore RD; Feinstein MJ; Burkholder GA; Mugavero MJ; Eron JJ; Saag MS; Kitahata MM; Crane HM; Whitney BM
J Acquir Immune Defic Syndr; 2022 May; 90(1):50-55. PubMed ID: 35001042
[TBL] [Abstract][Full Text] [Related]
20. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
